Dermata Therapeutics

Dermata Therapeutics received FDA approval for the proprietary name Xyngari (formerly DMT310) for its Phase 3 acne treatment. Xyngari, a once-weekly topical product derived from a freshwater sponge, aims to be a safe and effective acne treatment. Topline results from the first Phase 3 STAR-1 study are expected in March 2025.

Dermata Therapeutics (DRMA) has a clinical trial catalyst for its lead asset, DMT310, a topical acne treatment derived from Spongilla lacustris. DMT310 is in phase III trials, with STAR-1 nearing enrollment completion and results expected in Q1 2025. DMT410, using Spongilla technology for botulinum toxin delivery, has completed phase I trials. Dermata reported a Q3 2024 net loss of $3.2 million, with $6.1 million in cash expected to fund operations through Q1 2025.

DelveInsight's 'Rosacea Pipeline Insight, 2024' report highlights 25+ key companies developing 25+ pipeline drugs for Rosacea, with therapies in various stages of clinical development. Key companies include Sol-Gel Technologies, Maruho Co., Ltd., AOBiome LLC, and others. Emerging therapies like Epsolay, M 1220, and BMX-010 are expected to impact the market. Regulatory approvals and collaborations are noted, such as Sol-Gel Technologies' agreement with Searchlight Pharma Inc. and Zydus Lifesciences' FDA approval for Metronidazole Topical cream.

Dermata Therapeutics' CEO, Gerry Proehl, to present at the 2024 Maxim Healthcare Virtual Summit on Oct 15, 3:30PM ET, discussing the Phase 3 acne program and participating in a Q&A session.